文献速递浆细胞疾病淋巴瘤

达拉非尼联合曲美替尼治疗BRAFV600E突变肿瘤:NCI-MATCH试验H子方案结果

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
PubMed 文献 · J Clin Oncol · 2020-08-06

NCI-MATCH平台试验H子方案(EAY131-H)是一项开放标签单臂研究,纳入35例携带BRAFV600突变的实体瘤、淋巴瘤或多发性骨髓瘤患者(排除黑色素瘤、甲状腺癌、结直肠癌,后排除非小细胞肺癌),接受达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次治疗。29例纳入主要疗效分析,确认的客观缓解率为38%(90% CI 22.9%–54.9%,P<.0001,对照无效假设5%),中位无进展生存期11.4个月(90% CI 8.4–16.3),中位总生存期28.6个月。

要点

  • 确认的客观缓解率为38%(90% CI 22.9%–54.9%),P<.0001,对照无效假设5%。
  • 中位无进展生存期11.4个月(90% CI 8.4–16.3),中位总生存期28.6个月。
  • 缓解见于7种不同肿瘤类型,7例缓解持续时间>12个月,其中4例>24个月。

核心结论

  • 本研究达到主要终点,在该混合组织学、经治队列中客观缓解率为38%(P<.0001)。
  • 这一有前景的活性值得在目前获批适应证之外的BRAFV600突变肿瘤中进一步研究。

研究设计与样本

  • EAY131-H是NCI-MATCH平台试验的H子方案,为开放标签、单臂研究。
  • 纳入携带BRAFV600突变的实体瘤、淋巴瘤或多发性骨髓瘤患者,排除黑色素瘤、甲状腺癌、结直肠癌,后经修订排除非小细胞肺癌。
  • 患者接受达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次持续治疗,直至疾病进展或不可耐受毒性。
  • 主要终点为中央评估的客观缓解率,次要终点包括无进展生存期、6个月无进展生存期和总生存期。
  • 共入组35例患者,按方案预设29例纳入主要疗效分析;中位年龄59岁,45%的患者接受过≥3线治疗。

主要发现

  • 确认的客观缓解率为38%(90% CI 22.9%–54.9%),P<.0001,对照无效假设5%。
  • 中位无进展生存期11.4个月(90% CI 8.4–16.3个月)。
  • 缓解见于7种不同肿瘤类型。
  • 7例患者缓解持续时间>12个月,其中4例>24个月;另有8例患者无进展生存期>6个月。
  • 中位总生存期28.6个月;报告的不良事件与既往达拉非尼和曲美替尼已知安全性特征相当。

关键数值与推荐

  • 确认的客观缓解率为38%(90% CI 22.9%–54.9%),P<.0001,对照无效假设5%。
  • 中位无进展生存期11.4个月(90% CI 8.4–16.3个月)。
  • 中位总生存期28.6个月。
  • 7例患者缓解持续时间>12个月,其中4例>24个月。
  • 8例患者无进展生存期>6个月。

临床怎么用

  • 作者认为,该研究达到主要终点,客观缓解率为38%(P<.0001),这一有前景的活性值得在目前获批适应证之外的BRAFV600突变肿瘤中进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BRAFV600 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the MEK1/2 inhibitor trametinib in patients with solid tumors, lymphomas, or multiple myeloma whose tumors harbored a BRAFV600 mutation. PATIENTS AND METHODS: EAY131-H is an open-label, single-arm study. Patients with melanoma, thyroid, or colorectal cancer were excluded; patients with non-small-cell lung cancer were later excluded in an amendment. Patients received dabrafenib 150 mg twice per day and trametinib 2 mg per day continuously until disease progression or intolerable toxicity. The primary end point was centrally assessed objective response rate (ORR); secondary end points included progression-free survival (PFS), 6-month PFS, and overall survival. RESULTS: Thirty-five patients were enrolled, and 29 were included in the primary efficacy analysis as prespecified in the protocol. Median age was 59 years, and 45% of the patients had received ≥ 3 lines of therapy. The confirmed ORR was 38% (90% CI, 22.9% to 54.9%) with P < .0001 against a null rate of 5%, and PFS was 11.4 months (90% CI, 8.4 to 16.3 months); responses were seen in 7 distinct tumor types. Seven patients had a duration of response of > 12 months, including 4 patients with a duration of response of > 24 months. An additional 8 patients had a PFS > 6 months. The median overall survival was 28.6 months. Reported adverse events were comparable to those noted in previously reported profiles of dabrafenib and trametinib. CONCLUSION: This study met its primary end point, with an ORR of 38% (P < .0001) in this mixed histology, pretreated cohort. This promising activity warrants additional investigations in BRAFV600-mutated tumors outside of currently approved indications.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol. 2020. PMID: 32758030. doi:10.1200/JCO.20.00762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。